Speaker Profile
MD, Chief Medical Officer, Chief Quality Officer, Baylor Genetics
Biography
Dr. Christine Eng serves as the Chief Medical Officer and Chief Quality Officer at Baylor Genetics. She is Vice Chair for Diagnostic Laboratory Affairs in Molecular and Human Genetics at Baylor College of Medicine in Houston, TX, where she is also a professor. She is a trained pediatrician and medical geneticist. Dr. Eng has been recognized for contributions to the implementation of genomics in clinical practice. She is the senior author of articles in the New England Journal of Medicine and the Journal of American Medical Association regarding exome sequencing. In addition, she is the principal investigator of the genome sequencing core for the National Institutes of Healths Undiagnosed Diseases Network, and was elected to the Board of Directors of the American Society of Human Genetics effective January 1, 2024.
Talk
Addressing the Burden of Undiagnosed Disease
The NIHs Undiagnosed Diseases Network (UDN), together with sequencing core Baylor Genetics, is tackling the most challenging medical mysteries. Learn how the UDN brings together clinical and research experts and advanced technologies to help patients and families living with the burden of undiagnosed disease.
Clinical Dx Showcase:
Baylor Genetics
Baylor Genetics provides diagnostic answers to complex medical conditions and rare diseases. The company specializes in rapid Whole Genome Sequencing and Whole Exome Sequencing and complementary panels. Baylor Genetics works to transform healthcare and improve lives by converting scientific innovations into accessible clinical solutions.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
